The FDA approved Regeneron's gene therapy, Otarmeni, on April 23, the first-ever treatment to restore hearing in children born deaf due to a genetic mutation. It doesn't mask the problem; it fixes the instruction.
Why it matters
Millions of people live with inherited hearing loss. The FDA's approval makes a gene therapy available to restore function in the human ear, and the results exceeded predictions.
- 11 out of 12 children gained hearing after an infusion
- Three children could detect whispers
- Scientists expected the window for treatment to close in childhood. It didn't. Two 16-year-olds showed improvement.
"In my wildest dreams I never thought we'd be here in my lifetime," —Lawrence Lustig, MD, a Columbia University hearing specialist speaking to the Wall Street Journal
How it works
The therapy targets a faulty gene that prevents a protein inside the ear's hair cells from forming. The ears detect sound, but they can't send the signal to the brain.
- Otarmeni delivers a working copy of this gene into the inner ear.
- The ear's isolated structure made it easier to target safely than other organs
- One child screamed in the bathtub a month post-infusion and grabbed his ear, terrified by his own voice. It was working.
The backstory
Regeneron has worked on this since 2017, through a partnership with biotech Decibel Therapeutics, which it later acquired. The original approach — injecting proteins to stimulate nerve growth — failed, but replacing the missing gene worked.
By the numbers
- 20–50 U.S. newborns carry this mutation annually.
- The FDA used a priority voucher to compress the standard 10–12 month review to weeks.
- The company committed $27 billion to domestic R&D and manufacturing with the Trump administration under a separate pricing deal.
Yes, but:
- The trial enrolled 12 children. That's it.
- The durability of Otarmeni is unknown.
- Published reports include no adverse events.
The big picture
Regeneron plans to test the same mechanism in other types of hearing loss and in obesity and diabetes.
"This is more about a long-term investment in technology that will, hopefully, at some point, help thousands if not millions." —George Yancopoulos, chief scientific officer, Regeneron
The bottom line
One infusion. Twelve kids. Eleven heard sound. Will the treatment hold, and who else can it reach?
Protect and preserve your hearing
Hearing loss doesn't mean losing your balance, social world, or increasing your risk of dementia. Our free 15-minute hearing screening will help you:
- Understand your current hearing health
- Prevent communication barriers
- Stay engaged with loved ones
- Maintain your quality of life
Schedule your free screening today and rediscover the sounds that matter most.
★ Call 708-599-9500 to schedule your free screening.
★ For facts about hearing loss and hearing aid options, grab your copy of The Hearing Loss Guide.
★ Sign up for our newsletter for the latest on Hearing aids, dementia triggered by hearing loss, pediatric speech and hearing, speech-language therapies, Parkinson's Voice therapies, and occupational-hearing conservation. We publish our newsletter eight times a year.
Don't let untreated hearing loss spoil your enjoyment of life.
Crest Hill, IL - 630-633-5060 | Palos Hills, IL - 708-599-9500
Go deeper: WSJ: FDA Approves First-Ever Gene Therapy to Restore Hearing →
